Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), has received medical device registration certificates from the National Medical Products Administration for two in vitro diagnostic products, enhancing its product offerings and competitive position in the market [1]. Product Development - The newly registered products include the Adenovirus Antigen Test Kit (Colloidal Gold Method) and the Nucleic Acid Test Kit for Seven Respiratory Pathogens (Fluorescent PCR Method) [1]. - The acquisition of these medical device registration certificates expands the company's product range in the in vitro diagnostic field [1]. Market Positioning - The introduction of these products aims to meet diverse clinical needs, thereby strengthening the company's overall competitiveness [1]. - This development is expected to improve the company's market expansion capabilities [1].

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), has received a medical device registration certificate from the National Medical Products Administration for two in vitro diagnostic products, enhancing its product offerings and competitive position in the market [1] Product Development - The newly registered products include the Adenovirus Antigen Test Kit (Colloidal Gold Method) and the Nucleic Acid Test Kit for Seven Respiratory Pathogens (Fluorescent PCR Method) [1] - The acquisition of these medical device registration certificates expands the company's portfolio in the in vitro diagnostic field [1] Market Positioning - The introduction of these products aims to meet diverse clinical needs, thereby strengthening the company's overall competitiveness [1] - This development is expected to enhance the company's market expansion capabilities [1]